|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Real estate, at cost: | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Buildings and improvements | ||||||||||||||||||||
| Construction in progress | ||||||||||||||||||||
| Total real estate, at cost | ||||||||||||||||||||
| Less accumulated depreciation | ||||||||||||||||||||
| Net real estate held for investment | ||||||||||||||||||||
| Life science investments | ||||||||||||||||||||
| Construction loan receivable | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Right of use office lease asset | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| In-place lease intangible assets, net | ||||||||||||||||||||
| Other assets, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Exchangeable Senior Notes, net | ||||||||||||||||||||
| Notes due 2026, net | ||||||||||||||||||||
| Exchangeable notes, net | ||||||||||||||||||||
| Term loans, net | ||||||||||||||||||||
| Revolving credit facilities | ||||||||||||||||||||
| Building improvements and construction funding payable | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Rent received in advance and tenant security deposits | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, par value $0.001 per share, 50,000,000 shares authorized: 9.00% Series A cumulative redeemable preferred stock, liquidation preference of $25.00 per share, 5,666,082 and 2,019,525 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Common stock, par value $0.001 per share, 50,000,000 shares authorized: 27,571,349 and 28,022,975 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Dividends in excess of earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
